
Corcept Therapeutics (CORT) Stock Forecast & Price Target
Corcept Therapeutics (CORT) Analyst Ratings
Bulls say
Corcept Therapeutics Inc exhibits a promising financial outlook, with projected risk-adjusted sales expected to reach $171 million in 2026 and peak sales estimated at $1.9 billion by 2031. The company has notably increased its market penetration estimate for relacorilant in ovarian cancer from 20% to 25%, fueled by robust survival data and favorable FDA approval outcomes. Additionally, the anticipated launch of relacorilant, coupled with a dedicated sales force, underscores the company's strategic position to capitalize on market opportunities in oncology and beyond.
Bears say
Corcept Therapeutics's stock outlook appears negative due to several fundamental issues, including a significant decline in the 12-month price target from $105 to $67 per diluted share, reflecting concerns over the company's future revenue potential and increased execution risk. The Complete Response Letter for relacorilant in Cushing’s syndrome has contributed to a sharp decline in share value, alongside anticipated pricing pressure on Korlym sales due to court rulings, which may further impact financial performance in 2026. Additionally, management turnover raises concerns regarding the continuity and progress of clinical development, potentially leading to further adverse effects on share performance in a volatile political and regulatory landscape.
This aggregate rating is based on analysts' research of Corcept Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Corcept Therapeutics (CORT) Analyst Forecast & Price Prediction
Start investing in Corcept Therapeutics (CORT)
Order type
Buy in
Order amount
Est. shares
0 shares